APLP2 CRISPR/Cas9 KO Plasmid (h): sc-406400
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- APLP2 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the APLP2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
APLP2 CRISPR/Cas9 KO Plasmid (h) | sc-406400 | 20 µg | $397.00 |
Overview
APLP2 (amyloid beta precursor-like protein 2) is a type I transmembrane glycoprotein in the APP family that undergoes proteolytic processing and participates in membrane protein trafficking, cell adhesion, and cell–cell signaling. It localizes to secretory and endocytic compartments and has been linked to regulation of endocytosis, synaptic and neuronal development processes, and proteostasis pathways. APLP2 can modulate interactions with extracellular matrix components and intracellular adaptor proteins, influencing cytoskeletal organization and receptor turnover. Altered APP-family biology, including APLP2 expression and processing, is studied in contexts such as neurobiology and cancer cell phenotypes where changes in adhesion, migration, and survival signaling are relevant.
APLP2 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the APLP2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the APLP2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the APLP2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish APLP2 protein expression.
This CRISPR knockout system enables efficient generation of APLP2-deficient cell models for investigation of APLP2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting APLP2 exon(s) critical for APLP2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple APLP2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by APLP2 CRISPR/Cas9 KO Plasmid (h) and APLP2 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the APLP2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by APLP2 HDR Plasmid (h) and APLP2 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by APLP2 homology arms to support homology-directed repair at defined APLP2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.